Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
AB Sciex
Bio-Rad Diabetes Division

Key Genetic Error Found in Blood Cancer Groups

By Labmedica International staff writers
Posted on 12 Jan 2012
A critical genetic mutation has been revealed in some patients within a family of blood cancers that can progress to a fatal form of leukemia.

This family of blood cancers is known as myelodysplastic syndromes and are a difficult-to-treat type of blood disease that occur when blood cells in the bone marrow do not mature properly.

A scientific team at the Washington University School of Medicine (St. Louis, MO, USA) discovered the mutation in a gene known as small nuclear ribonucleic acid (RNA) auxiliary factor 1(U2AF1). They sequenced the entire genome of a 65-year old man with myelodysplastic syndrome that had progressed to leukemia and compared it with the genome of his tumor cells.

After identifying the U2AF1 mutation in three patients through whole-genome sequencing, the investigators scoured the gene for the mutation in another 150 patients with myelodysplastic syndromes. They identified the mutation in 13, or nearly 9% of the patients. The mutations were acquired during development of myelodysplastic syndromes because they were not present in normal cells obtained from each patient. Patients were almost three times as likely to develop leukemia if they had a mutation in the U2AF1 gene. The disorder progressed to leukemia in 15.2% of patients with the mutation, compared with 5.8% of those without the genetic anomaly.

Normally, the U2AF1 gene makes a protein involved in splicing RNA, a sister molecule of DNA that carries the instructions for building proteins. Splicing brings together different sections of RNA necessary to make a protein and discards those sections that are not needed. The mutated version of the gene still produces a protein, but its splicing activity is altered, which may be important for the development of some cancers.

Timothy Graubert, MD, an associate professor of medicine and senior author of the study said, "A mutation in any one of these eight genes occurs in up to 50% of patients with myelodysplastic syndromes. Because these changes are so common, we think there are likely to be implications for improving the diagnosis of the disorder and finding new therapeutic options." Myelodysplastic syndromes are hematopoietic stem cell disorders that often progress to chemotherapy-resistant secondary acute myeloid leukemia. About 28,000 Americans are diagnosed with the disorder each year, most of them over the age of 60. The study was published on December 11, 2011, in the journal Nature Genetics.

Related Links:
Washington University School of Medicine



77 ELEKTRONIKA
PURITAN MEDICAL
DiagCor Bioscience
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: The Cobas 6000 Multipurpose Clinical Laboratory analyzer (Photo courtesy of Roche Diagnostics).

Low Density Lipoprotein Apolipoprotein-B Assay Validated

The relationship between apolipoprotein-B (Apo-B) concentration and the risk of developing cardiovascular disease (CVD) is more robust than the relationship between low density lipoprotein cholesterol... Read more

Microbiology

view channel

Novel Sequence Analysis Services Improve Pathogen Identification

A set of new-generation sequencing (NGS) services provides unique tools for more effective identification of known and unknown microorganisms, including bacterial, viral, fungal, and protozoan parasite pathogens. Aperiomics (Ashburn, VA, USA) has now introduced its breakthrough Absolute-NGS Pathogen Detection Platform... Read more

Industry News

view channel

Market for qPCR Exceeds USD 3 Billion

The market for real-time quantitative polymerase chain reaction (qPCR) was valued at about USD 3.2 billion for 2013 according to Kalorama Information (New York, NY, USA) an increase from USD 2.8 billion in 2011. The healthcare market researcher said that the testing system is considered the workhorse of research providing... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.